GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Centessa Pharmaceuticals PLC (STU:260) » Definitions » Policy Acquisition Expense

Centessa Pharmaceuticals (STU:260) Policy Acquisition Expense


View and export this data going back to 2021. Start your Free Trial

What is Centessa Pharmaceuticals Policy Acquisition Expense?

Policy Acquisition Expense only applies to insurance companies.


Centessa Pharmaceuticals (STU:260) Business Description

Traded in Other Exchanges
Address
1 Ashley Road, 3rd Floor, Altrincham, Cheshire, GBR, WA14 2DT
Centessa Pharmaceuticals PLC is a clinical-stage pharmaceutical company. The company's pipeline assets include 1) SerpinPC for Hemophilia A, B, 2) LB101 for Solid Tumors, 3) ORX750 for Narcolepsy Type 1 (NT1) and other sleep disorders, 4) MGX292 Pulmonary Arterial Hypertension (PAH) and 5) Undisclosed for Solid Tumors.